Sleep

Patients aged 7 years and older can now be treated for their cataplexy or excessive daytime sleepiness with the extended-release oral formulation.

Treatment with tirzepatide has led not only to significant reductions in excess body weight, but also improvements in blood pressure and reduction of inflammatory markers.

AI-enabled remote cardiac monitoring offers continuous data on heart activity, allowing for the early detection of arrhythmias, optimized treatment timing, and improved sleep-related heart health management.

Poor sleep quality is directly related to mortality risk before adjusting for lifestyle or health-related factors, and dementia was noticeably linked to mortality risk in older White males.

Pharmacists can help identify potential drug-drug interactions and adverse reactions, and advise patients when to seek further treatment

The ADA Clinical Practice Recommendations added sleep assessment for precision medicine in type 2 diabetes, supporting the wealth of information surrounding the association.

The findings show that those with higher plasma homocysteine concentrations experienced more sleep apnea events per hour compared with those with lower concentrations.

Based on these results, tirzepatide could be first medication approved for treatment of obstructive sleep apnea in patients with obesity.

Despite the finding, the authors suggest further research is done to better understand the mechanisms behind the interactions between asthma, sleep, and depression.

With the current social media trend of the “Sleepy-Girl Mocktail” claiming to provide quality sleep, is this trend fact or faux as a quality sleep aid?

Eli Lilly and Company will submit results of the study to support tirzepatide (Zepbound) for treatment of obstructive sleep apnea later this year.

Several studies on valerian have been conducted in the past 50 years for indications varying from insomnia, anxiety, restless leg syndrome, headaches, and more.

Stephanie Ashraf, MD, offered clinical experience in managing insomnia at the American Medical Women’s Association (AMWA) 2024 Annual Meeting.

In some instances, metabolites can predict risk in patients who still have normal glucose biomarkers.

Investigators found genetic evidence that certain sleep behaviors can be risk factors for lifespan.

Increased waist circumference and high blood pressure can disrupt circadian rhythm, which can increase risk of progression to poor renal outcomes.

Benzodiazepines have proven effective in managing anxiety and insomnia, but they heighten risk of falls, cognitive impairment, functional decline, and mortality among older adults.

Because medications to treat these conditions are often controlled substances, including pharmacists on the multidisciplinary team (MDT) is invaluable.

The risk of poor cognitive performance was nearly double in participants who had the greatest number of sleep disturbances compared to the least.

Sleep duration is positively associated with quality of life in adolescents.

The majority (86.7%) of patients in the study got less than 7 hours of sleep each night.

Moderate cycling improved cognitive function in patients who got partial or no sleep.

Conducting clinical trials to investigate claims regarding supplements' safety and efficacy can support greater patient wellness.

Only 20% of the patient population were reported as being “very good” sleepers when it comes to sleep disturbances.

Neuroimaging showed that people who lacked sleep had altered risk-taking behaviors.

Melatonin is not fully regulated by the FDA, and there are concerns about children taking the supplement due to associated risks, such as dependency and overdose.

This FDA clearance comes about 11 months after another clearance for appliances to treat mild-to-moderate obstructive sleep apnea (OSA)—the first clearance for oral appliances to treat OSA with supplemental therapies.

The genes that predispose a person to sleep problems can impact that person across their entire lifetime, so interventions targeted toward a younger audience could be beneficial.

According to 2020 data from the CDC, about 14.5% of adults reported having trouble falling asleep most or every day during the 30 days prior to the survey.